AKTX logo

Akari Therapeutics (AKTX)

Profile

Full Name

Akari Therapeutics, Plc

Ticker Symbol

AKTX

Exchange

NASDAQ

Country

United States

IPO

January 6, 2014

Indexes

Not included

Employees

8

Key Details

Price

$1.45(-0.68%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

$0.00(0.00% YoY)

PE ratio

-

Next earnings date

May 16, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Dec 5, 22 HC Wainwright & Co.
Buy
Nov 1, 22 Alliance Global Partners
Buy
Mar 13, 20 B. Riley Securities
Buy
Mar 13, 20 B. Riley FBR
Buy
May 5, 18 B. Riley FBR
Neutral
Mar 29, 18 Canaccord Genuity
Buy
Feb 8, 18 B. Riley Securities
Neutral
Feb 8, 18 B. Riley FBR
Neutral
Sep 22, 17 William Blair
Outperform
May 31, 17 Chardan Capital
Neutral

Institutional Ownership

  • What is the ticker symbol for Akari Therapeutics?
  • Does Akari Therapeutics pay dividends?
  • What sector is Akari Therapeutics in?
  • What industry is Akari Therapeutics in?
  • What country is Akari Therapeutics based in?
  • When did Akari Therapeutics go public?
  • Is Akari Therapeutics in the S&P 500?
  • Is Akari Therapeutics in the NASDAQ 100?
  • Is Akari Therapeutics in the Dow Jones?
  • When was Akari Therapeutics's last earnings report?
  • When does Akari Therapeutics report earnings?
  • Should I buy Akari Therapeutics stock now?

What is the ticker symbol for Akari Therapeutics?

The ticker symbol for Akari Therapeutics is NASDAQ:AKTX

Does Akari Therapeutics pay dividends?

No, Akari Therapeutics does not pay dividends

What sector is Akari Therapeutics in?

Akari Therapeutics is in the Healthcare sector

What industry is Akari Therapeutics in?

Akari Therapeutics is in the Biotechnology industry

What country is Akari Therapeutics based in?

Akari Therapeutics is headquartered in United States

When did Akari Therapeutics go public?

Akari Therapeutics's initial public offering (IPO) was on January 6, 2014

Is Akari Therapeutics in the S&P 500?

No, Akari Therapeutics is not included in the S&P 500 index

Is Akari Therapeutics in the NASDAQ 100?

No, Akari Therapeutics is not included in the NASDAQ 100 index

Is Akari Therapeutics in the Dow Jones?

No, Akari Therapeutics is not included in the Dow Jones index

When was Akari Therapeutics's last earnings report?

Akari Therapeutics's most recent earnings report was on Apr 16, 2025

When does Akari Therapeutics report earnings?

The next expected earnings date for Akari Therapeutics is May 16, 2025

Should I buy Akari Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page